Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (39)

2024

  1. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

  2. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  3. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  4. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

    Clinical Lymphoma, Myeloma and Leukemia

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014

  3. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  4. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

2020

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

  2. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2019

  1. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

    British Journal of Haematology

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560

  2. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217

2016

  1. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30

  2. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39

  3. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma

    New England Journal of Medicine, Vol. 375, Núm. 14, pp. 1319-1331

  4. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557